Protein C News and Research

RSS

Scientists discover two HIV variants in cerebrospinal fluid of HAD patients

When the virus that causes AIDS infects the central nervous system, it can lead to the development of a severe neurological disease called HIV- associated dementia.

7 Oct 2011

NCKU research team discovers potential target to treat osteoporosis

A National Cheng Kung University (NCKU) research team has discovered that a protein called interleukin (IL)-20 is a key to treating osteoporosis, a disease that lowers a person's bone density.

7 Oct 2011

Hysterectomy increases brain iron levels in both men and women

The human body has a love-hate relationship with iron. Just the right amount is needed for proper cell function, yet too much is associated with brain diseases like Alzheimer's and Parkinson's.

7 Oct 2011

Scientists discover new metabolic pathway which makes gliomas more aggressive

A research alliance of Heidelberg University Hospital and the German Cancer Research Center, jointly with colleagues of the Helmholtz Center for Environmental Research in Leipzig, have discovered a new metabolic pathway which makes malignant brain tumors (gliomas) more aggressive and weakens patients' immune systems.

7 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.

6 Oct 2011

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories U.S.A., Inc. (TRL). The companies will collaborate to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies to the identified therapeutic targets.

4 Oct 2011

Muscle cannot be functionally reactivated if you're too late

When a motor nerve is severely damaged, people rarely recover full muscle strength and function. Neuroscientists from Children's Hospital Boston, combining patient data with observations in a mouse model, now show why. It's not that motor nerve fibers don't regrow – they can – but they don't grow fast enough. By the time they get to the muscle fibers, they can no longer communicate with them.

4 Oct 2011

Virus DNA uncoated with aid of host cell

They have been around since the dawn of time and are a model of evolutionary success: viruses. Viruses are extremely adaptable but they have a problem: They cannot reproduce, so they smuggle their genes into suitable host cells. In the case of some viruses, the viral DNA has to enter the cell nucleus to reproduce. This has been known for almost 50 years.

4 Oct 2011

Lipomannan on TB bacterium's outer cell surface can block TNF production

The bacterium that causes tuberculosis has a unique molecule on its outer cell surface that blocks a key part of the body's defense. New research suggests this represents a novel mechanism in the microbe's evolving efforts to remain hidden from the human immune system.

4 Oct 2011

DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine

The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say.

4 Oct 2011

Alzheimer's may originate in a form similar to that of infectious prion diseases

The brain damage that characterizes Alzheimer's disease may originate in a form similar to that of infectious prion diseases such as bovine spongiform encephalopathy (mad cow) and Creutzfeldt-Jakob, according to newly published research by The University of Texas Health Science Center at Houston.

4 Oct 2011

Researchers apply new approach to take a close look at amyloid plaque formation

Researchers at the University of Toronto Scarborough (UTSC) and Osaka University applied a new approach to take a close look at amyloid plaque formation, a process that plays important roles in Alzheimer's disease.

4 Oct 2011

Researchers identify new enzyme function that may protect against anemia

Researchers at St. Michael's Hospital have discovered a new function for an enzyme that may protect against organ injury and death from anemia.

4 Oct 2011

Discovery of ‘alarm-clock’ gene

Researchers led by Indian-American scientist, Satchidananda Panda at the Salk Institute for Biological Studies in La Jolla, Calif., said the gene is responsible for starting the body’s biological clock from its restful state every morning. They add that this may open avenues in research in insomnia or sleeplessness, aging and chronic illnesses.

3 Oct 2011

Novel drug shows promise for MLL leukemia

According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.

3 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011